Russia flu diagnostic and treatment market is projected to grow at a CAGR of 1.48% throughout the forecast period. The flu diagnostics and treatment market in Russia is poised to grow on account of the availability of a highly advanced healthcare system in the country. Russian government ensures that free health services are available adequately to the citizens of the country through via Obligatory Medical Insurance (OMI). In addition, the seasonal prevalence of influenza is also projected to positively impact the market growth during the next five years. The healthcare services are majorly free throughout the country on account the compulsory state health insurance program. However, the organizational structure coupled with limited government funding further leads to affect the healthcare in the country thereby expected to moderately impact the flu diagnostic and treatment market growth.
Furthermore, the continuously growing incidence of seasonal flu across the country is one of the key factors which is expected to supplement the market growth throughout the forecast period and beyond. Moreover, the growing adoption of private healthcare on account of the presence of state-of-art private healthcare is further leading to the adoption of costly treatment and services as numerous private facilities are expanding their services to the people with insurance also. The unavailability of the required services from the public health system of the country is further leading to high adoption of private healthcare services in the country which is leading to a surge in the out-of-pocket expenditure. The continuous growth in the out-of-pocket expenditure also shows the potential for the market growth of flu diagnostic and treatment during the coming years. For instance, in Russia, the out-of-pocket expenditure (% of current health expenditure) reached 40.485% by 2016 from 31.127% in 2006. This in turn is boosting the adoption of private health insurance which is significantly increasing the adoption of highly advanced private healthcare services by the people which is also projected to significantly drive the flu diagnostic and treatment market growth in Russian Federation during the next five years.
Russia flu diagnostic and treatment market has been segmented on the basis of the type of flu, offering, age group, and end-user. On the basis of the type of flu, the market has been classified on the basis of type A and type B. By offering, the market has been segmented into diagnostics and therapeutics. By the age group the market has been segmented on the basis of 0-14 years, 15-64 years and >=65 years. By the end-user, the segmentation has been done on the basis of hospital laboratory, outpatient clinic, and reference laboratory.
Prominent key market players in Russia flu diagnostic and treatment market include Abbott, F. Hoffmann-La Roche Ltd, and 3M. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in Russia flu diagnostic and treatment market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.